Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2007 Oct;8(15):2569-78.

The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.

Author information

  • University of Chicago, Pritzker School of Medicine, Executive Medical Director, Radiant Research, Chicago, IL, USA. michaeldavidson@radiantresearch.com

Abstract

Bile-acid sequestrants augment cholesterol excretion via enhanced conversion to bile acids, and act to lower low-density lipoprotein cholesterol (LDL-C), especially when combined with other cholesterol-lowering drugs. Colesevelam hydrochloride (HCL) has become the preferred drug of this class due to fewer gastrointestinal adverse effects. This article reviews the use of colesevelam in the treatment of dyslipidemia. Bile-acid sequestrants are a class of drugs developed to lower LDL-C levels. Two of the bile-acid sequestrants, colestyramine resin and colestipol, have been used since the 1980s, and have proven effective and safe as nonsystemic approaches to cholesterol reduction. However, tolerability and compliance issues related to palatability and gastrointestinal side effects have limited the use of these sequestrants. Colesevelam HCL (Daiichi Sankyo, Inc., Parsippany, NJ) is a nonabsorbed lipid-lowering agent that can be used in monotherapy or in combination with an HMG-CoA reductase inhibitor to reduce LDL-C in patients with primary hypercholesterolemia (Fredrickson type IIa). This article reviews the clinical efficacy and use of colesevelam HCL for the management of dyslipidemia.

PMID:
17931091
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk